F10 and atrial fibrillation: The majority of cohort in the current study had an intermediate risk of stroke (49.6) compared to average CHADS2 scores of 3.27 and 3.2 in J-ROCKET AF, ROCKET AF (rivaroxaban once daily oral direct Factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation), respectively (Patel et al., 2011; Hori et al., 2012).